达格列净联合阿托伐他汀治疗糖尿病性心肌病的疗效观察  

Effects of daggligin combined with atorvastatin on diabetes cardiomyopathy

作　　者：陈伟刚[1] 齐玉婕 吴鹏宇 王昆仑[1] 常学伟[1] Chen Weigang;Qi Yujie;Wu Pengyu;Wang Kunlun;Chang Xuewei(Department of Cardiovascular,Luoyang Central Hospital,Luoyang,Henan 471000,China)

机构地区：[1]洛阳市中心医院心血管内科,河南洛阳471000

出　　处：《中国药物与临床》2025年第4期256-260,共5页Chinese Remedies & Clinics

摘　　要：目的探讨达格列净联合阿托伐他汀在糖尿病性心肌病(DCM)中的疗效。方法选择河南省洛阳市中心医院2020年6月至2023年6月收治的120例DCM患者,按随机数字表法分为对照组(阿托伐他汀)与观察组(阿托伐他汀联合达格列净)。均持续治疗6个月,随访6个月。对比2组临床疗效、心室重构指标[左心室舒张末期容积指数(LVEDVI)、左心室收缩末期容积指数(LVESVI)以及左心室质量指数(LVMI)]、糖脂代谢指标[餐后2 h血糖(2 h PG)、空腹血糖(FBG)、总胆固醇(TC)及三酰甘油(TG)]、心功能指标[左室射血分数(LVEF)、左室收缩末期前后径(LVEDs)、左室舒张末期内径(LVEDd)]、心肌标志物[心肌肌钙蛋白T(cTnT)、心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)]及不良反应。结果观察组临床总有效率(58/60,96.7%)高于对照组(51/60,85.0%),治疗后LVEDVI、LVESVI、LVMI水平均低于对照组,2 h PG、FBG、TC及TG水平均低于对照组,LVEDs、LVEDd水平均低于对照组,LVEF水平均高于对照组,cTnT、cTnI、CK-MB指标水平均低于对照组,差异均有统计学意义(P<0.05)。结论达格列净联合阿托伐他汀治疗DCM的疗效显著,可改善糖脂代谢指标、心室重构及心肌标志物指标水平,促进心脏功能恢复,且应用安全性较好。Objective To explore the efficacy of daggligin combined with atorvastatin in the treatment of diabetes cardiomyopathy(DCM).Methods A total of 120 patients with DCM admitted to our hospital from June 2020 to June 2023 were selected and divided into a control group(atorvastatin)and an observation group(atorvastatin combined with daggligin)using a random number table method.All patients were treated continuously for 6 months and followed up for another 6 months.The clinical efficacy,ventricular remodeling indicators[left ventricular end-diastolic volume index(LVEDVI),left ventricular end-systolic volume index(LVESVI),and left ventricular mass index(LVMI)],glycemic and lipid metabolic indicators[2-hour postprandial glucose(2 h PG),fasting blood glucose(FBG),total cholesterol(TC),and triglycerides(TG)],cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVEDs),and left ventricular end-diastolic diameter(LVEDd)],myocardial markers[cardiac troponin T(cTnT),cardiac troponin I(cTnI),and creatine kinase-MB(CK-MB)],and adverse reactions were compared between the two groups.Results The clinical total effective rate of the observation group(96.7%)was higher than that of the control group(85.0%).After treatment,the levels of LVEDVI,LVESVI,and LVMI in the observation group were lower than those in the control group.The levels of PG,FBG,TC,and TG at 2 hours in the observation group were lower than those in the control group.The average levels of LVEDs and LVEDd in the observation group were lower than those in the control group,and the levels of LVEF in the observation group were higher than those in the control group.The levels of cTnT,cTnI,and CK-MB in the observation group were lower than those in the control group.All the differences were statistically significant(P<0.05).Conclusion The combination of dapagliflozin and atorvastatin has significant therapeutic effects on DCM,improving glucose and lipid metabolism indicators,ventricular remodeling,and myocardial marker le

关 键 词：糖尿病心肌病 达格列净 阿托伐他汀 治疗结果 心室重构 药物相关性副作用和不良反应 

分 类 号：R542.2[医药卫生—心血管疾病] R587.2[医药卫生—内科学]